Page 1338 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 3

61. Mitchell EP. Gastrointestinal toxicity of chemotherapeutic 79. LoMonaco M, Milone M, Batocchi AP, Padua L, Restuccia D,
agents. Semin Oncol. February 2006;33(1):106-120. Tonali P. Cisplatin neuropathy: clinical course and neurophysi-
62. Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemo- ological findings. J Neurol. April 1992;239(4):199-204.
therapy. Semin Oncol. February 2006;33(1):50-67. 80. Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML,
63. Aloia TA, Fahy BN. Chemotherapy-associated hepatotoxicity: Kiernan MC. Oxaliplatin-induced neurotoxicity: changes in
how concerned should we be? Expert Rev Anticancer Ther. April axonal excitability precede development of neuropathy. Brain.
2010;10(4):521-527. October 2009;132(pt 10):2712-2723.
64. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, 81. Ocean AJ, Vahdat LT. Chemotherapy-induced peripheral
Abdalla EK. Chemotherapy-associated hepatotoxicity and neuropathy: pathogenesis and emerging therapies. Support Care
surgery for colorectal liver metastases. Br J Surg. March 2007; Cancer. September 2004;12(9):619-625.
94(3):274-286. 82. Schiff D, Wen PY, van den Bent MJ. Neurological adverse effects
65. Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol.
of defibrotide in 88 patients after stem cell transplantation with October 2009;6(10):596-603.
severe veno-occlusive disease and multisystem organ failure: 83. Garcia-Marco JA, Panizo C, Garcia ES, et al. Efficacy and safety
response without significant toxicity in a high-risk popula- of liposomal cytarabine in lymphoma patients with central
tion and factors predictive of outcome. Blood. December 15, nervous system involvement from lymphoma. Cancer. May 1,
2002;100(13):4337-4343. 2009;115(9):1892-1898.
66. Richardson PG, Soiffer RJ, Antin JH, et al. Defibrotide for the 84. Benesch M, Urban C. Liposomal cytarabine for leukemic and
treatment of severe hepatic veno-occlusive disease and mul- lymphomatous meningitis: recent developments. Expert Opin
tiorgan failure after stem cell transplantation: a multicenter, Pharmacother. February 2008;9(2):301-309.
randomized, dose-finding trial. Biol Blood Marrow Transplant. 85. Chamberlain MC. Neurotoxicity of cancer treatment. Curr
July 2010;16(7):1005-1017. Oncol Rep. January 2010;12(1):60-67.
67. Bulley SR, Strahm B, Doyle J, Dupuis LL. Defibrotide for the 86. Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF.
treatment of hepatic veno-occlusive disease in children. Pediatr Safety of anticoagulation use and bevacizumab in patients with
Blood Cancer. June 15, 2007;48(7):700-704. glioma. Neuro Oncol. June 2008;10(3):355-360.
68. Osanto S, Bukman A, Van Hoek F, Sterk PJ, De Laat JA, 87. Plotkin SR, Wen PY. Neurologic complications of cancer ther-
Hermans J. Long-term effects of chemotherapy in patients with apy. Neurol Clin. February 2003;21(1):279-318, x.
testicular cancer. J Clin Oncol. April 1992;10(4):574-579. 88. Zanotti KM, Markman M. Prevention and management of
69. Hartmann JT, Fels LM, Knop S, Stolt H, Kanz L, Bokemeyer C. antineoplastic-induced hypersensitivity reactions. Drug Saf.
A randomized trial comparing the nephrotoxicity of cisplatin/ 2001;24(10):767-779.
ifosfamide-based combination chemotherapy with or without
amifostine in patients with solid tumors. Invest New Drugs. 89. Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-
August 2000;18(3):281-289. foot skin reaction, palmar-plantar erythrodysesthesia): focus on
sorafenib and sunitinib. Oncology. 2009;77(5):257-271.
70. Hartmann JT, Knop S, Fels LM, et al. The use of reduced
doses of amifostine to ameliorate nephrotoxicity of cisplatin/ 90. Payne AS, James WD, Weiss RB. Dermatologic toxicity of
ifosfamide-based chemotherapy in patients with solid tumors. chemotherapeutic agents. Semin Oncol. February 2006;33(1):
Anticancer Drugs. January 2000;11(1):1-6. 86-97.
71. Kintzel PE. Anticancer drug-induced kidney disorders. Drug 91. Goolsby TV, Lombardo FA. Extravasation of chemotherapeu-
Saf. January 2001;24(1):19-38. tic agents: prevention and treatment. Semin Oncol. February
2006;33(1):139-143.
72. Hamdi T, Latta S, Jallad B, Kheir F, Alhosaini MN, Patel A.
Cisplatin-induced renal salt wasting syndrome. South Med J. 92. Rickles FR, Levine MN. Epidemiology of thrombosis in cancer.
August 2010;103(8):793-799. Acta Haematol. 2001;106(1-2):6-12.
73. Russo P. Urologic emergencies in the cancer patient. Semin 93. Hernandez RK, Sorensen HT, Pedersen L, Jacobsen J, Lash TL.
Oncol. 2000;27(3):284-298. Tamoxifen treatment and risk of deep venous thrombosis and
pulmonary embolism: a Danish population-based cohort study.
74. Klastersky J. Side effects of ifosfamide. Oncology. 2003;65 Cancer. October 1, 2009;115(19):4442-4449.
(suppl 2):7-10. 94. Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular
75. Widemann BC, Balis FM, Kempf-Bielack B, et al. High- events in patients with urothelial transitional cell carcinoma
dose methotrexate-induced nephrotoxicity in patients with treated with cisplatin based chemotherapy. J Urol. December
osteosarcoma. Cancer. May 15, 2004;100(10):2222-2232. 1998;160(6 pt 1):2021-2024.
76. Kapoor M, Chan GZ. Malignancy and renal disease. Crit Care 95. Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler
Clin. July 2001;17(3):571-598, viii. WM. A high rate of venous thromboembolism in a multi-
77. Buchen S, Ngampolo D, Melton RG, et al. Carboxypeptidase institutional phase II trial of weekly intravenous gemcitabine
G2 rescue in patients with methotrexate intoxication and renal with continuous infusion fluorouracil and daily thalidomide in
failure. Br J Cancer. 2005;92(3):480-487. patients with metastatic renal cell carcinoma. Cancer. October
78. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. 15, 2002;95(8):1629-1636.
Diagnosis, management, and evaluation of chemotherapy-induced 96. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of
peripheral neuropathy. Semin Oncol. February 2006;33(1):15-49. deep-vein thrombosis in patients with multiple myeloma

Section07-O-ref.indd 3 1/21/2015 11:26:52 AM